Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S.
Rogé M, et al. Among authors: pointreau y.
Clin Transl Radiat Oncol. 2023 Mar 8;40:100613. doi: 10.1016/j.ctro.2023.100613. eCollection 2023 May.
Clin Transl Radiat Oncol. 2023.
PMID: 36968576
Free PMC article.